154 related articles for article (PubMed ID: 37713687)
1. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
2. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
4. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Song AB; Al-Samkari H
Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Grace RF
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
[TBL] [Abstract][Full Text] [Related]
7. Updates and advances in pyruvate kinase deficiency.
Luke N; Hillier K; Al-Samkari H; Grace RF
Trends Mol Med; 2023 May; 29(5):406-418. PubMed ID: 36935283
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
9. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
11. Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency.
Kanno H; Utsugisawa T; Aizawa S; Koizumi T; Aisaki K; Hamada T; Ogura H; Fujii H
Haematologica; 2007 Jun; 92(6):731-7. PubMed ID: 17550844
[TBL] [Abstract][Full Text] [Related]
12. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.
De SK
Curr Med Chem; 2024; 31(6):683-687. PubMed ID: 37125655
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
Grace RF; Bianchi P; van Beers EJ; Eber SW; Glader B; Yaish HM; Despotovic JM; Rothman JA; Sharma M; McNaull MM; Fermo E; Lezon-Geyda K; Morton DH; Neufeld EJ; Chonat S; Kollmar N; Knoll CM; Kuo K; Kwiatkowski JL; Pospíšilová D; Pastore YD; Thompson AA; Newburger PE; Ravindranath Y; Wang WC; Wlodarski MW; Wang H; Holzhauer S; Breakey VR; Kunz J; Sheth S; Rose MJ; Bradeen HA; Neu N; Guo D; Al-Sayegh H; London WB; Gallagher PG; Zanella A; Barcellini W
Blood; 2018 May; 131(20):2183-2192. PubMed ID: 29549173
[TBL] [Abstract][Full Text] [Related]
15. Molecular heterogeneity of pyruvate kinase deficiency.
Bianchi P; Fermo E
Haematologica; 2020 Sep; 105(9):2218-2228. PubMed ID: 33054047
[TBL] [Abstract][Full Text] [Related]
16. [From gene to disease; hereditary non-spherocytic hemolytic anemia caused by pyruvate kinase deficiency].
de Vooght KM; van Wijk R; Nieuwenhuis HK; Ploos van Amstel JK; Rijksen G; van Solinge WW
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1828-31. PubMed ID: 12382367
[TBL] [Abstract][Full Text] [Related]
17. Management of pyruvate kinase deficiency in children and adults.
Grace RF; Barcellini W
Blood; 2020 Sep; 136(11):1241-1249. PubMed ID: 32702739
[TBL] [Abstract][Full Text] [Related]
18. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial.
Andrae DA; Grace RF; Jewett A; Foster B; Klaassen RJ; Salek S; Li J; Tai F; Boscoe AN; Zagadailov E
J Patient Rep Outcomes; 2023 Nov; 7(1):112. PubMed ID: 37943362
[TBL] [Abstract][Full Text] [Related]
19. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme.
van Dijk MJ; de Wilde JRA; Bartels M; Kuo KHM; Glenthøj A; Rab MAE; van Beers EJ; van Wijk R
Blood Rev; 2023 Sep; 61():101103. PubMed ID: 37353463
[TBL] [Abstract][Full Text] [Related]
20. Hereditary erythrocyte pyruvate-kinase (PK) deficiency and chronic hemolytic anemia: clinical, genetic and molecular studies in six new Spanish patients.
Vives-Corrons JL; Marie J; Pujades MA; Kahn A
Hum Genet; 1980; 53(3):401-8. PubMed ID: 7372343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
